PIK3CA MUTATION
Clinical trials for PIK3CA MUTATION explained in plain language.
Never miss a new study
Get alerted when new PIK3CA MUTATION trials appear
Sign up with your email to follow new studies for PIK3CA MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New precision drug targets Cancer's genetic weakness
Disease control Recruiting nowThis is a first-in-human study testing a new targeted drug called RLY-2608. It aims to find a safe and effective dose for patients with advanced solid tumors or breast cancer that have a specific genetic mutation called PIK3CA. The study will test the drug by itself and in combin…
Matched conditions: PIK3CA MUTATION
Phase: PHASE1 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Targeted drug trial offers hope for rare growth disorders
Disease control Recruiting nowThis study is testing an experimental drug called RLY-2608 in adults and children with rare conditions that cause abnormal tissue overgrowth due to a specific genetic mutation. The research aims to find the right dose, check safety, and see if the drug can reduce the size of over…
Matched conditions: PIK3CA MUTATION
Phase: PHASE2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope for advanced breast cancer patients after standard treatment fails
Disease control Recruiting nowThis global Phase 3 trial is testing which of two drug combinations works better to control advanced breast cancer that has a specific genetic change (PIK3CA mutation) and has worsened after standard hormone therapy. It will enroll about 540 adults whose cancer has returned or sp…
Matched conditions: PIK3CA MUTATION
Phase: PHASE3 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC